Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth (Status and Outlook) 2026-2032
The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.
United States market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key GLP-1 Agonists for the Treatment of both Diabetes and Obesity players cover Novo Nordisk, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Forecast? looks at past sales and reviews total world GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales in 2025, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales for 2026 through 2032. With GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonists for the Treatment of both Diabetes and Obesity industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on GLP-1 Agonists for the Treatment of both Diabetes and Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonists for the Treatment of both Diabetes and Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonists for the Treatment of both Diabetes and Obesity market by product type, application, key players and key regions and countries.
Segmentation by Type:
GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.
United States market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key GLP-1 Agonists for the Treatment of both Diabetes and Obesity players cover Novo Nordisk, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Forecast? looks at past sales and reviews total world GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales in 2025, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales for 2026 through 2032. With GLP-1 Agonists for the Treatment of both Diabetes and Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonists for the Treatment of both Diabetes and Obesity industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on GLP-1 Agonists for the Treatment of both Diabetes and Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonists for the Treatment of both Diabetes and Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonists for the Treatment of both Diabetes and Obesity market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Semaglutide
- Liraglutide
- Tirzepatide
- Hospital and Clinic
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- Eli Lilly
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
2.1.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Country/Region (2021, 2025 & 2032)
2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type
2.2.1 Semaglutide
2.2.2 Liraglutide
2.2.3 Tirzepatide
2.2.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
2.2.4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Retail Pharmacies
2.3.3 Other
2.3.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
2.3.4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
3 GLP-1 AGONISTS FOR THE TREATMENT OF BOTH DIABETES AND OBESITY MARKET SIZE BY PLAYER
3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Player
3.1.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Player (2021-2026)
3.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Player (2021-2026)
3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GLP-1 AGONISTS FOR THE TREATMENT OF BOTH DIABETES AND OBESITY BY REGION
4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026)
4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Annual Revenue by Country/Region (2021-2026)
4.3 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
4.4 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
4.5 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
4.6 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
5.2 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
5.3 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026)
6.2 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
6.3 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Region (2021-2026)
8.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
8.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GLP-1 AGONISTS FOR THE TREATMENT OF BOTH DIABETES AND OBESITY MARKET FORECAST
10.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.1.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.1.2 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.1.3 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.1.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.1.5 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Country (2027-2032)
10.2.1 United States Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2.2 Canada Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2.3 Mexico Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2.4 Brazil Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.3.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast
10.3.2 Japan Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.3 Korea Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.4 Southeast Asia Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.5 India Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.6 Australia Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Country (2027-2032)
10.4.1 Germany Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.2 France Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.3 UK Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.4 Italy Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.5 Russia Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.5.1 Egypt Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5.2 South Africa Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5.3 Israel Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5.4 Turkey Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.6 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Type (2027-2032)
10.7 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Application (2027-2032)
10.7.1 GCC Countries Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
11.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
11.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
2.1.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Country/Region (2021, 2025 & 2032)
2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type
2.2.1 Semaglutide
2.2.2 Liraglutide
2.2.3 Tirzepatide
2.2.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
2.2.4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Retail Pharmacies
2.3.3 Other
2.3.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
2.3.4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
3 GLP-1 AGONISTS FOR THE TREATMENT OF BOTH DIABETES AND OBESITY MARKET SIZE BY PLAYER
3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Player
3.1.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Player (2021-2026)
3.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Player (2021-2026)
3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GLP-1 AGONISTS FOR THE TREATMENT OF BOTH DIABETES AND OBESITY BY REGION
4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026)
4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Annual Revenue by Country/Region (2021-2026)
4.3 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
4.4 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
4.5 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
4.6 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
5.2 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
5.3 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026)
6.2 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
6.3 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Region (2021-2026)
8.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
8.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GLP-1 AGONISTS FOR THE TREATMENT OF BOTH DIABETES AND OBESITY MARKET FORECAST
10.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.1.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.1.2 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.1.3 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.1.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.1.5 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2 Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Country (2027-2032)
10.2.1 United States Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2.2 Canada Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2.3 Mexico Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.2.4 Brazil Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3 APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.3.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast
10.3.2 Japan Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.3 Korea Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.4 Southeast Asia Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.5 India Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.3.6 Australia Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Country (2027-2032)
10.4.1 Germany Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.2 France Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.3 UK Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.4 Italy Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.4.5 Russia Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Region (2027-2032)
10.5.1 Egypt Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5.2 South Africa Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5.3 Israel Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.5.4 Turkey Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
10.6 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Type (2027-2032)
10.7 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast by Application (2027-2032)
10.7.1 GCC Countries Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
11.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
11.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Semaglutide
Table 4. Major Players of Liraglutide
Table 5. Major Players of Tirzepatide
Table 6. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Table 9. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 11. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Table 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Player (2021-2026) & ($ millions)
Table 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Player (2021-2026)
Table 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Head office and Products Offered
Table 15. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & ($ millions)
Table 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Table 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Country (2021-2026)
Table 24. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Table 26. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Table 28. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Table 30. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Country (2021-2026)
Table 34. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Table 40. Key Market Challenges & Risks of GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Table 41. Key Industry Trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Table 42. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Novo Nordisk Details, Company Type, GLP-1 Agonists for the Treatment of both Diabetes and Obesity Area Served and Its Competitors
Table 47. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
Table 48. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Novo Nordisk Main Business
Table 50. Novo Nordisk Latest Developments
Table 51. Eli Lilly Details, Company Type, GLP-1 Agonists for the Treatment of both Diabetes and Obesity Area Served and Its Competitors
Table 52. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
Table 53. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Eli Lilly Main Business
Table 55. Eli Lilly Latest Developments
Table 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Semaglutide
Table 4. Major Players of Liraglutide
Table 5. Major Players of Tirzepatide
Table 6. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Table 9. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 11. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Table 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Player (2021-2026) & ($ millions)
Table 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Player (2021-2026)
Table 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Head office and Products Offered
Table 15. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & ($ millions)
Table 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Table 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Country (2021-2026)
Table 24. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Table 26. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Table 28. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Table 30. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Country (2021-2026)
Table 34. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Table 40. Key Market Challenges & Risks of GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Table 41. Key Industry Trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Table 42. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Novo Nordisk Details, Company Type, GLP-1 Agonists for the Treatment of both Diabetes and Obesity Area Served and Its Competitors
Table 47. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
Table 48. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Novo Nordisk Main Business
Table 50. Novo Nordisk Latest Developments
Table 51. Eli Lilly Details, Company Type, GLP-1 Agonists for the Treatment of both Diabetes and Obesity Area Served and Its Competitors
Table 52. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Offered
Table 53. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Eli Lilly Main Business
Table 55. Eli Lilly Latest Developments
LIST OF FIGURES
Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Market Share by Country/Region (2025)
Figure 8. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type in 2025
Figure 10. GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Hospital and Clinic
Figure 11. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Hospital and Clinic (2021-2026) & ($ millions)
Figure 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Retail Pharmacies
Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Retail Pharmacies (2021-2026) & ($ millions)
Figure 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Other
Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Other (2021-2026) & ($ millions)
Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application in 2025
Figure 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Player in 2025
Figure 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Figure 19. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 20. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 21. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 23. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Value Market Share by Country in 2025
Figure 24. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region in 2025
Figure 29. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Figure 30. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Figure 31. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 35. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Country in 2025
Figure 38. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Figure 39. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Figure 40. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 41. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 42. UK GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Figure 48. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 54. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 55. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 57. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 58. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 59. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 60. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 61. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 62. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 63. Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 65. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 66. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 67. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 68. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 69. UK GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 70. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 71. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 72. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 73. South Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 74. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 75. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 76. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Market Share by Country/Region (2025)
Figure 8. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type in 2025
Figure 10. GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Hospital and Clinic
Figure 11. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Hospital and Clinic (2021-2026) & ($ millions)
Figure 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Retail Pharmacies
Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Retail Pharmacies (2021-2026) & ($ millions)
Figure 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Other
Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Other (2021-2026) & ($ millions)
Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application in 2025
Figure 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Player in 2025
Figure 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Figure 19. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 20. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 21. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2021-2026 ($ millions)
Figure 23. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Value Market Share by Country in 2025
Figure 24. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region in 2025
Figure 29. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Figure 30. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Figure 31. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 35. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Country in 2025
Figure 38. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Figure 39. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Figure 40. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 41. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 42. UK GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share by Application (2021-2026)
Figure 48. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 54. APAC GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 55. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 57. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 58. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 59. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 60. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 61. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 62. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 63. Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 65. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 66. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 67. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 68. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 69. UK GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 70. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 71. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 72. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 73. South Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 74. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 75. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
Figure 76. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size 2027-2032 ($ millions)
